Oragenics, Inc. (OGEN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oragenics, Inc. (OGEN) trades at $0.54 with AI Score 28/100 (Grade F). Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and vaccines to combat infectious diseases. Market cap: $2.44M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 5, 2026Analyst Coverage for OGEN: OGEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OGEN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OGEN: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oragenics, Inc. (OGEN) Healthcare & Pipeline Overview
Oragenics, Inc. is a biotechnology firm specializing in the development of innovative antibiotics and vaccines, including intranasal and intramuscular coronavirus vaccine candidates, positioning it within the competitive infectious disease therapeutics market. The company also explores treatments for dental caries and weight management.
What Is the Investment Thesis for OGEN?
Oragenics, Inc. presents a speculative investment opportunity within the biotechnology sector, primarily driven by its vaccine candidates targeting SARS-CoV-2. The potential success of NT-CoV2-1 and Terra CoV-2 could significantly impact the company's valuation. However, the company's market capitalization is $0.00B, and it operates in a highly competitive and regulated environment. Key value drivers include successful clinical trial outcomes and strategic partnerships. Upcoming milestones for its vaccine candidates, such as Phase 1 trial results, will be critical. The company's small size and limited resources pose ongoing risks, including potential delays in development timelines and challenges in securing funding. The company's beta is 1.21.
Based on FMP financials and quantitative analysis
OGEN Key Highlights
Oragenics is focused on developing vaccines and antibiotics for infectious diseases.
- The company's lead vaccine candidates include NT-CoV2-1 (intranasal) and Terra CoV-2 (intramuscular) targeting SARS-CoV-2.
- Oragenics has a license agreement with Noachis Terra Inc. for coronavirus spike protein technology.
- The company has a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development of MU1140 and related homologs.
- Oragenics is also developing LPT3-04 for weight loss and SMaRT Replacement Therapy for dental caries prevention.
Who Are OGEN's Competitors?
OGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| MRNA Moderna, Inc. | $139.86 | -19.80% | $55.5B | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OGEN's Key Strengths?
Innovative vaccine and antibiotic development programs.
- Strategic collaborations with other companies.
- Focus on addressing unmet medical needs.
- Proprietary technologies and intellectual property.
What Are OGEN's Weaknesses?
Limited financial resources.
- Small number of employees.
- Dependence on collaborations and partnerships.
- Early-stage development programs with high risk of failure.
What Could Drive OGEN Stock Higher?
Clinical trial results for NT-CoV2-1 intranasal vaccine candidate.
- Clinical trial results for Terra CoV-2 intramuscular vaccine candidate.
- Potential partnerships or licensing agreements for product candidates.
- Development of SMaRT Replacement Therapy for dental caries prevention.
- Collaboration with Precigen, Inc. and ILH Holdings, Inc. for MU1140 development.
What Are the Key Risks for OGEN?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for vaccine and antibiotic candidates.
- Regulatory delays or rejection of product candidates.
- Limited financial resources and dependence on external funding.
- Intense competition from larger pharmaceutical companies.
- Intellectual property disputes or challenges.
What Are the Growth Opportunities for OGEN?
- Growth opportunity 1: Successful development and commercialization of NT-CoV2-1, the intranasal vaccine candidate, represents a significant growth opportunity. The global market for COVID-19 vaccines is projected to remain substantial, driven by the need for booster shots and protection against emerging variants. If Oragenics can demonstrate the safety and efficacy of NT-CoV2-1, it could capture a portion of this market, potentially generating significant revenue. Timeline: Clinical trials are ongoing, with potential for commercialization within the next 2-3 years.
- Growth opportunity 2: Advancing Terra CoV-2, the intramuscular vaccine candidate, provides another avenue for growth. While the market for initial COVID-19 vaccinations may be saturated, there is still a demand for alternative vaccine options, particularly those that offer improved safety or efficacy. If Terra CoV-2 can differentiate itself from existing vaccines, it could gain market share. Timeline: Clinical trials are ongoing, with potential for commercialization within the next 3-4 years.
- Growth opportunity 3: The development and commercialization of SMaRT Replacement Therapy for dental caries prevention presents a distinct growth opportunity. The global market for dental caries treatments is substantial, driven by the high prevalence of dental caries worldwide. If Oragenics can demonstrate the effectiveness of SMaRT Replacement Therapy, it could capture a portion of this market. Timeline: Preclinical development is ongoing, with potential for clinical trials within the next 2-3 years.
- Growth opportunity 4: The collaboration with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs represents a strategic growth opportunity. MU1140 is a novel antibiotic with the potential to address antibiotic-resistant infections, a growing global health threat. Successful development and commercialization of MU1140 could generate significant revenue for Oragenics. Timeline: Development is ongoing, with potential for clinical trials within the next 2-3 years.
- Growth opportunity 5: Exploring strategic partnerships and licensing agreements for its existing and future product candidates is a critical growth opportunity for Oragenics. By partnering with larger pharmaceutical companies, Oragenics can leverage their resources and expertise to accelerate the development and commercialization of its products. This approach can also provide Oragenics with upfront payments, milestone payments, and royalties, generating additional revenue streams. Timeline: Ongoing, with potential for new partnerships and agreements in the near future.
What Threats Does OGEN Face?
- Intense competition from larger pharmaceutical companies.
- Lengthy and costly regulatory approval processes.
- Clinical trial failures.
- Changes in government regulations and healthcare policies.
What Are OGEN's Competitive Advantages?
- Proprietary vaccine and antibiotic technologies.
- Strategic collaborations with other companies.
- Intellectual property protection through patents and licenses.
- Focus on addressing unmet medical needs in infectious diseases.
What Does OGEN Do?
Oragenics, Inc., incorporated in 1996 and headquartered in Tampa, Florida, is a biotechnology company dedicated to developing novel treatments for infectious diseases. The company's primary focus is on the development and commercialization of vaccines and antibiotics. Its lead vaccine candidates include NT-CoV2-1, an intranasal vaccine designed to provide immunity against the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), and Terra CoV-2, an intramuscular vaccine targeting the same virus. These vaccine programs represent a significant portion of Oragenics' research and development efforts. In addition to its vaccine programs, Oragenics is also developing LPT3-04, a weight loss candidate, and SMaRT Replacement Therapy, a topical treatment aimed at preventing dental caries. These programs reflect the company's broader interest in addressing unmet medical needs through innovative therapeutic approaches. Oragenics has established strategic collaborations to advance its product pipeline. A license agreement with Noachis Terra Inc. grants Oragenics access to certain patent rights and biological materials related to the use of pre-fusion coronavirus spike proteins. Additionally, the company has a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. These collaborations are crucial for leveraging external expertise and resources to accelerate the development and commercialization of Oragenics' product candidates. Formerly known as Oragen, Inc., the company has evolved to focus on addressing critical healthcare challenges through innovative biotechnology solutions.
What Products and Services Does OGEN Offer?
- Develop intranasal and intramuscular vaccine candidates for SARS-CoV-2.
- Research and develop novel antibiotics to combat infectious diseases.
- Develop LPT3-04 as a weight loss candidate.
- Develop SMaRT Replacement Therapy for preventing dental caries.
- Collaborate with other companies to develop and commercialize pharmaceutical products.
- License patent rights and biological materials related to coronavirus spike proteins.
How Does OGEN Make Money?
- Develop and license pharmaceutical products.
- Generate revenue through collaboration agreements and partnerships.
- Seek funding through grants and investments to support research and development.
- Potentially generate revenue through direct sales of approved products.
What Industry Does OGEN Operate In?
Oragenics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for infectious disease treatments is substantial, driven by the ongoing threat of emerging pathogens and the increasing prevalence of antibiotic-resistant bacteria. Oragenics' focus on developing novel vaccines and antibiotics positions it to potentially capitalize on this growing market. However, the company faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios.
Who Are OGEN's Key Customers?
- Pharmaceutical companies through licensing agreements.
- Healthcare providers and patients, pending regulatory approval and commercialization of products.
- Research institutions through collaborations and partnerships.
How Oragenics, Inc. Is Valued
Relative to its peer group, OGEN's quantitative score of 28/100 is below the peer average of 78/100.
Company Profile
Oragenics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lakewood Ranch, US. The company is led by CEO Janet Huffman. OGEN has traded publicly since 2004.
Financial Health
Oragenics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Oragenics, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 65.2% above estimates on average.
Forward Outlook
Wall Street analysts project Oragenics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.69.
OGEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative vaccine and antibiotic development programs.
- Strategic collaborations with other companies.
- Focus on addressing unmet medical needs.
- Proprietary technologies and intellectual property.
Bear Case
- Limited financial resources.
- Small number of employees.
- Dependence on collaborations and partnerships.
- Early-stage development programs with high risk of failure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OGEN Latest News
No recent news available for OGEN.
OGEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OGEN.
Price Targets
Wall Street price target analysis for OGEN.
OGEN MoonshotScore
What does this score mean?
The MoonshotScore rates OGEN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Janet Huffman
Unknown
Janet Huffman currently manages a small team of three employees at Oragenics, Inc. Details regarding her prior career history, education, and previous roles are not available. Her background and experience in the biotechnology or pharmaceutical industry are unknown.
Track Record: Due to the limited information available, it is not possible to assess Janet Huffman's track record or identify key achievements, strategic decisions, or company milestones under her leadership at Oragenics, Inc.
Oragenics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for OGEN?
OGEN holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and vaccines to combat infectious diseases. Their pipeline includes vaccine candidates targeting coronaviruses …
What does Oragenics, Inc. do?
Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and vaccines to combat infectious diseases. Their pipeline includes NT-CoV2-1, an intranasal vaccine candidate, and Terra CoV-2, an intramuscular vaccine candidate, both targeting SARS-CoV-2. Additionally, they are developing LPT3-04 for weight loss and SMaRT Replacement Therapy for preventing dental caries.
What are the main risks for OGEN?
Oragenics faces several key risks inherent to the biotechnology industry. Clinical trial failures for its vaccine and antibiotic candidates represent a significant risk, as these programs are critical to the company's future success. Regulatory delays or rejection of product candidates could also negatively impact the company's prospects.
What are the key factors to evaluate for OGEN?
Oragenics, Inc. (OGEN) holds an AI score of 28/100 (low). presents a speculative investment opportunity within the biotechnology sector, primarily driven by its vaccine candidates targeting SARS-CoV-2. Not financial advice.
How frequently does OGEN data refresh on this page?
OGEN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OGEN's recent stock price performance?
Oragenics, Inc. (OGEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine and antibiotic development programs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OGEN overvalued or undervalued right now?
Oragenics, Inc. (OGEN) is loss-making, so its trailing P/E is negative (-0.3x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OGEN before investing?
Before investing in Oragenics, Inc. (OGEN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OGEN to a portfolio?
Key strength of Oragenics, Inc. (OGEN): Innovative vaccine and antibiotic development programs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- Market capitalization is very low, indicating high risk.
- Financial data is limited.